C4 Therapeutics, Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
C4 Therapeutics, Inc. (CCCC) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $7.65 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2022-05-05
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2022-03-31 was $7.65M, a 3.07% increase year-over-year.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2021-12-31 was $20.08M, a 143.02% increase year-over-year.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2021-09-30 was $8.50M, a 0.63% increase year-over-year.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2021-06-30 was $9.78M, a 1.15% increase year-over-year.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2021 was $45.78M, a 37.93% increase from fiscal 2020.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2020 was $33.20M, a 55.25% increase from fiscal 2019.
- C4 Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2019 was $21.38M.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2022-03-31 | $7.65M 10-Q · filed 2022-05-05 | $27.73M derived: sum of 2 quarters · filed 2022-05-05 | $36.23M derived: sum of 3 quarters · filed 2022-05-05 | $46.01M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $20.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $28.58M derived: sum of 2 quarters · filed 2022-02-24 | $38.36M derived: sum of 3 quarters · filed 2022-02-24 | $45.78M 10-K · filed 2022-02-24 |
| 2021-09-30 | $8.50M 10-Q · filed 2021-11-10 | $18.28M derived: sum of 2 quarters · filed 2021-11-10 | $25.71M 10-Q · filed 2021-11-10 | $33.97M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-06-30 | $9.78M 10-Q · filed 2021-08-11 | $17.21M 10-Q · filed 2021-08-11 | $25.47M derived: sum of 3 quarters · filed 2022-05-05 | $33.92M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | $7.43M 10-Q · filed 2022-05-05 | $15.69M derived: sum of 2 quarters · filed 2022-05-05 | $24.14M derived: sum of 3 quarters · filed 2022-05-05 | $33.80M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $16.71M derived: sum of 2 quarters · filed 2022-02-24 | $26.38M derived: sum of 3 quarters · filed 2022-02-24 | $33.20M 10-K · filed 2022-02-24 |
| 2020-09-30 | $8.45M 10-Q · filed 2021-11-10 | $18.12M derived: sum of 2 quarters · filed 2021-11-10 | $24.93M 10-Q · filed 2021-11-10 | $33.14M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $9.67M 10-Q · filed 2021-08-11 | $16.49M 10-Q · filed 2021-08-11 | $24.70M derived: sum of 3 quarters · filed 2022-02-24 | $30.06M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $6.82M 10-Q · filed 2021-05-13 | $15.03M derived: sum of 2 quarters · filed 2022-02-24 | $20.39M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $13.57M derived: sum of 2 quarters · filed 2022-02-24 | $21.38M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $5.36M 10-Q · filed 2020-11-12 | $13.17M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |